A Placebo‐Controlled Trial of Atomoxetine in Marijuana‐Dependent Individuals with Attention Deficit Hyperactivity Disorder
- 21 September 2010
- journal article
- research article
- Published by Wiley in The American Journal on Addictions
- Vol. 19 (6) , 481-489
Abstract
This study evaluated the effects of atomoxetine on the symptoms of attention deficit hyperactivity disorder (ADHD) and marijuana use in marijuana‐dependent adults. In conjunction with motivational interviewing, participants received either atomoxetine (n = 19) or matching placebo (n = 19) for 12 weeks. Participants randomized to atomoxetine had greater improvement in ADHD on the Clinical Global Impression‐Improvement scale than participants treated with placebo. No treatment group differences in self‐rated ADHD symptoms, overall Wender‐Reimherr Adult Attention Deficit Disorder Scale scores, or marijuana use outcomes were noted. These results suggest that atomoxetine may improve some ADHD symptoms but does not reduce marijuana use in this population. (Am J Addict 2010;00:1–9)Keywords
This publication has 47 references indexed in Scilit:
- The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse clinical trialsJournal of Substance Abuse Treatment, 2009
- Atomoxetine Treatment for Cocaine Abuse and Adult Attention Deficit/Hyperactivity Disorder (ADHD): A Preliminary Open TrialJournal of Dual Diagnosis, 2009
- Effect of Prior Stimulant Treatment for Attention-Deficit/Hyperactivity Disorder on Subsequent Risk for Cigarette Smoking and Alcohol and Drug Use Disorders in AdolescentsArchives of Pediatrics & Adolescent Medicine, 2008
- Atomoxetine treatment of adults with ADHD and comorbid alcohol use disordersDrug and Alcohol Dependence, 2008
- Atomoxetine for treatment of marijuana dependence: A report on the efficacy and high incidence of gastrointestinal adverse events in a pilot studyDrug and Alcohol Dependence, 2008
- Buspirone for Treatment of Marijuana Dependence: A Pilot StudyThe American Journal on Addictions, 2006
- Caution Regarding the Use of Pilot Studies to Guide Power Calculations for Study ProposalsArchives of General Psychiatry, 2006
- Neurotransmission of Cognition, Part 2: Selective NRIs Are Smart Drugs: Exploiting Regionally Selective Actionson Both Dopamine and Norepinephrineto Enhance CognitionThe Journal of Clinical Psychiatry, 2003
- Enhancing motivation for change in problem drinking: A controlled comparison of two therapist styles.Journal of Consulting and Clinical Psychology, 1993
- Longitudinal data analysis using generalized linear modelsBiometrika, 1986